Biosig Technologies (NASDAQ:STEX) Director Morgan Lee Lekstrom Buys 23,000 Shares of Stock

Biosig Technologies, Inc. (NASDAQ:STEX) Director Morgan Lee Lekstrom acquired 23,000 shares of Biosig Technologies stock in a transaction that occurred on Monday, January 26th. The stock was acquired at an average cost of $3.30 per share, for a total transaction of $75,900.00. Following the completion of the purchase, the director directly owned 71,000 shares of the company’s stock, valued at $234,300. This represents a 47.92% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Tuesday, January 27th, Morgan Lee Lekstrom purchased 5,500 shares of Biosig Technologies stock. The shares were bought at an average price of $3.12 per share, with a total value of $17,160.00.
• On Friday, January 23rd, Morgan Lee Lekstrom bought 41,000 shares of Biosig Technologies stock. The stock was purchased at an average cost of $3.13 per share, with a total value of $128,330.00.

Biosig Technologies Trading Up 7.4%

NASDAQ:STEX opened at $3.65 on Wednesday. Biosig Technologies, Inc. has a 1-year low of $0.40 and a 1-year high of $14.11.

Wall Street Analyst Weigh In

Separately, Weiss Ratings assumed coverage on Biosig Technologies in a research note on Friday. They issued a “sell (d-)” rating for the company. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Key Biosig Technologies News

Here are the key news stories impacting Biosig Technologies this week:

• Positive Sentiment: Major shareholder Frank Giustra bought 1,000,000 shares at $3.00 (≈$3.0M), increasing his direct stake to 1,178,205 shares — a large, confidence-signaling purchase disclosed to the SEC. SEC Filing
• Positive Sentiment: CIO Mitchell Young Williams acquired 51,511 shares at ~$3.03, raising his holdings to ~1,051,511 shares — another insider buy that supports management confidence. SEC Filing
• Positive Sentiment: Director Morgan Lee Lekstrom executed multiple purchases (including 41,000 and 23,000-share transactions at ~\$3.13–\$3.30), materially increasing her stake — another insider buy pattern reinforcing insider conviction. SEC Filing
• Neutral Sentiment: Press releases show closings of public offerings tied to the STEX ticker (announcements reporting $35M and $40.25M gross proceeds). If these refer to the same issuer, proceeds increase liquidity but also imply share issuance/dilution — impact depends on use of proceeds and whether this is the same corporate entity. Globe Newswire
• Negative Sentiment: Weiss Ratings initiated coverage with a “sell (d-)” rating, and MarketBeat shows an average analyst view of “Sell” — negative third‑party sentiment that can cap upside despite insider buying. Weiss Ratings

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.